Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 109 results for melanoma

  1. Monitoring and response biomarkers: Can biomarkers accurately classify recurrence, progression and response to treatment?

    analysis of melanoma tissue samples. Full details of the evidence and the committee's discussion are in evidence review A: genetic...

    Research recommendation
    Published
    4 August 2022

  2. Pembrolizumab with epacadostat for untreated malignant melanoma [ID1423]

    Discontinued Reference number: GID-TA10330

    Technology appraisal guidance
    Discontinued

  3. Artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway: early value assessment (HTG746)

    Early value assessment (EVA) guidance on artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway.

    HealthTech guidance
    Last updated
    17 March 2026
    View recommendations

    Sections for HTG746

  4. Temozolomide for the treatment of advanced and metastatic melanoma [ID316]

    Discontinued Reference number: GID-TAG401

    Technology appraisal guidance
    Discontinued

  5. V940 with pembrolizumab for adjuvant treatment of resected high-risk stage 2 to 4 melanoma [ID6674]

    Awaiting development Reference number: GID-TA11881 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Melanoma (metastatic) - paclitaxel albumin-bound nanoparticles (1st line) [ID570]

    Discontinued Reference number: GID-TAG440

    Technology appraisal guidance
    Discontinued

  7. Vemurafenib for treating resected BRAF V600 mutation-positive melanoma [ID1250]

    Discontinued Reference number: GID-TA10213

    Technology appraisal guidance
    Discontinued

  8. Atezolizumab with cobimetinib for untreated BRAF wild-type metastatic melanoma [ID1470]

    Discontinued Reference number: GID-TA10354

    Technology appraisal guidance
    Discontinued

  9. Techniques for confirming a diagnosis in people with suspected atypical Spitzoid melanocytic lesions: In people with reported atypical Spitzoid lesions, how effective are fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH) and tests to detect driver mutations compared with histopathological examination alone in predicting disease specific survival? This should be investigated ina prospective diagnostic study. Secondary outcomes should include sensitivity, specificity, accuracy, positive predictive value, disease specific survival and progression free survival.

    with expert review, but it is not always possible to distinguish Spitzoid melanoma from benign Spitzoid melanocytic lesions. Current...

    Research recommendation
    Published
    4 August 2022

  10. Talimogene laherparepvec with pembrolizumab for treating unresectable or metastatic melanoma [ID3856]

    Discontinued Reference number: GID-TA10836

    Technology appraisal guidance
    Discontinued

  11. Relatlimab with nivolumab for treating advanced malignant melanoma after immunotherapy in people over 12 [ID1612]

    Discontinued Reference number: GID-TA10484

    Technology appraisal guidance
    Discontinued

  12. Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer (TA904)

    Evidence-based recommendations on pembrolizumab (Keytruda) with lenvatinib (Lenvima) for treating advanced or recurrent endometrial cancer in adults.

    Technology appraisal guidance
    Published
    21 June 2023
    View recommendations

    Sections for TA904

  13. Nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma [ID1610]

    Discontinued Reference number: GID-TA10499

    Technology appraisal guidance
    Discontinued

  14. Melanoma (advanced, unresectable, metastatic, NRAS mutation positive) - binimetinib [ID833]

    Discontinued Reference number: GID-TA10074

    Technology appraisal guidance
    Discontinued

  15. Pelareorep for treating metastatic malignant melanoma after previous therapy [ID941]

    Discontinued Reference number: GID-TA10686

    Technology appraisal guidance
    Discontinued